3 Stocks to Invest in Before the Housing Market Crashes

 

The housing market might crash in the near term as mortgage demand remains under pressure because of low housing inventory and high-average 30-year fixed mortgage rates.

Homebuyers locked into the sub-5% pandemic-era mortgage rates simply aren’t selling. The total number of homes on the market for the four weeks ending September 3, 2023, has declined 18% year-over-year, registering the biggest decline since February 2022. Meanwhile, new listings fell 9.3%.

Prospective home buyers have also been thwarted by rising property prices, which have increased for five months in a row. According to the National Association of Realtors (NAR), more than half of U.S. metro areas registered home price gains in the second quarter of 2023. It also reported that the median sale prices of existing homes are near record highs.

Last month, mortgage rates climbed to their highest level in 23 years. Mortgage rates have risen as the Federal Reserve undertook aggressive interest rate hikes since last year to curb high inflation. The weekly average of the 30-year fixed-rate mortgage as of September 7, 2023, stood at 7.12%.

The high mortgage rates led to mortgage applications reaching the lowest level since 1996. According to the Mortgage Bankers Association’s (MBA) Weekly Mortgage Applications Survey for the week ending September 1, 2023, mortgage applications fell 2.9% compared to the prior week.

MBA’s Vice President and Deputy Chief Economist Joel Kan said, “Mortgage applications declined to the lowest level since December 1996, despite a drop in mortgage rates. Both purchase and refinance applications fell, with the purchase index hitting a 28-year low, as prospective buyers remain on the sidelines due to low housing inventory and elevated mortgage rates.”

Freddie Mac’s chief economist Sam Khater said, “The economy remains buoyant, which is encouraging for consumers. Though inflation has decelerated, firmer economic data have put upward pressure on mortgage rates, which are straining potential homebuyers in the face of affordability challenges.”

Although nonfarm payrolls increased by 187,000 in August, the unemployment rate was 3.8%, up surprisingly from 3.5% in July. If unemployment keeps rising, it could lead to missed mortgage payments and foreclosures. With skyrocketing mortgage rates, high housing prices, and the possibility of a recession between now and July 2024 at 59%, a housing market crash is highly likely.

In the event of a housing crash, defensive stocks such as Walmart Inc. (WMT), American Water Works Company, Inc. (AWK), and Eagle Materials Inc. (EXP) will likely help cushion one’s portfolio. The products and services these companies provide are always in demand, irrespective of the economic cycles.

Let’s discuss these stocks in detail.

Walmart Inc. (WMT)

WMT engages in the operation of retail, wholesale, and other units worldwide. The company operates through three segments: Walmart U.S., Walmart International, and Sam's Club. 

WMT’s revenue grew at a CAGR of 5.2% over the past three years. Its EBITDA grew at a CAGR of 3.3% over the past three years. In addition, its EBIT grew at a CAGR of 4.6% in the same time frame.

In terms of the trailing-12-month Return on Common Equity, WMT’s 17.87% is 58.5% higher than the 11.28% industry average. Its 5.50% trailing-12-month Return on Total Assets is 28.1% higher than the 4.30% industry average. Likewise, its 2.51x trailing-12-month asset turnover ratio is 176.2% higher than the industry average of 0.91x.

WMT’s total revenues for the second quarter ended July 31, 2023, increased 5.9% year-over-year to $161.63 billion. The company’s adjusted operating income rose 8.1% over the prior-year quarter to $7.41 billion.

In addition, its consolidated net income attributable to WMT increased 53.3% over the prior-year quarter to $7.89 billion. Also, its adjusted EPS came in at $1.84, representing an increase of 4% year-over-year.

Analysts expect WMT’s EPS and revenue for the quarter ending October 31, 2023, to increase 0.7% and 4.5% year-over-year to $1.51 and $158.22 billion, respectively. It surpassed the Street EPS estimates in each of the trailing four quarters. Over the past year, the stock has gained 19.2% to close the last trading session at $164.52.

American Water Works Company, Inc. (AWK)

AWK provides water and wastewater services. It offers water and wastewater services to approximately 1,600 communities in 14 states, serving approximately 3.4 million active customers. The company serves residential customers; commercial customers, including food and beverage providers, commercial property developers and proprietors, and energy suppliers; fire service and private fire customers; etc.

AWK’s revenue grew at a CAGR of 3.1% over the past three years. Its net income grew at a CAGR of 11.9% over the past three years. In addition, its EPS grew at a CAGR of 10.9% in the same time frame.

In terms of the trailing-12-month gross profit margin, AWK’s 58.97% is 51.7% higher than the 38.86% industry average. Its 22.08% trailing-12-month net income margin is 133.6% higher than the 9.46% industry average. Likewise, its 10.35% trailing-12-month Return on Common Equity is 19% higher than the industry average of 8.70%.

For the fiscal second quarter ended June 30, 2023, AWK’s operating revenues increased 17.1% year-over-year to $1.10 billion. Its operating income rose 32.1% year-over-year to $432 million. The company’s net income attributable to common shareholders increased 28.4% over the prior year quarter to $280 million. Also, its EPS came in at $1.44, representing an increase of 20% year-over-year.

For the quarter ending September 30, 2023, AWK’s EPS and revenue are expected to increase 0.2% and 7.3% year-over-year to $1.63 and $1.16 billion, respectively. It surpassed the Street EPS estimates in three of the trailing four quarters. Over the past six months, the stock has gained 2.9% to close the last trading session at $137.56.

Eagle Materials Inc. (EXP)

EXP manufactures and sells heavy construction materials and light building materials. It operates in four segments: Cement, Concrete and Aggregates, Gypsum Wallboard, and Recycled Paperboard. The company engages in the mining of limestone for the manufacture, production, distribution, and sale of Portland cement; grinding and sale of slag; and mining of gypsum for the manufacture and sale of gypsum wallboards.

On May 3, 2023, EXP announced the completion of the acquisition of Martin Marietta’s cement import and distribution business in Northern California, including a cement terminal in Stockton, California. The acquisition bodes well for the company as it will help extend and strengthen its distribution reach across its heartland U.S. cement manufacturing system.

EXP’s President and CEO, Michael Haack, said, “Our Nevada Cement operations have long-standing customer relationships in Northern California, and this acquisition will uniquely position us to better serve these and new customers with complementary imported product.”

“Our entire cement system is currently ‘sold out’, and this acquisition will enable us to more actively participate in the strong US demand environment. Our experience as a cement importer elsewhere in the US is a transferrable expertise at Eagle, and we expect a smooth ownership transition,” he added.

EXP’s EBIT grew at a CAGR of 24.4% over the past three years. Its net income grew at a CAGR of 56% over the past three years. In addition, its levered FCF grew at a CAGR of 54.7% in the same time frame.

In terms of the trailing-12-month net income margin, EXP’s 21.82% is 230.7% higher than the 6.60% industry average. Its 13.32% trailing-12-month levered FCF margin is 269.3% higher than the 3.61% industry average. Likewise, its 34.36% trailing-12-month EBITDA margin is 98.7% higher than the industry average of 17.29%.

EXP’s revenue for the first quarter ended June 30, 2023, increased 7.1% year-over-year to $601.52 million. The company’s adjusted net earnings rose 17.2% over the prior-year quarter to $126.15 million. Its adjusted EPS came in at $3.55, representing an increase of 25.9% year-over-year. Also, its adjusted EBITDA increased 16.4% year-over-year to $214.29 million.

Street expects EXP’s EPS and revenue for the quarter ending September 30, 2023, to increase 13.5% and 4.9% year-over-year to $4.24 and $634.84 million, respectively. Over the past year, the stock has gained 48.4% to close the last trading session at $180.19.

CVS Health (CVS) Shakes up Pharma Market With Potential Biosimilar Game-Changer: Buy or Hold?

Biosimilars have been gaining traction lately as healthcare costs continue to rise. Biosimilars are attractive for healthcare companies as they can vie for a more significant share of the pie, given the extensive market for critical life-saving drugs. Fortune Business Insights expects the U.S. biosimilars market size to grow at a CAGR of 40.2% to reach $100.75 billion by 2029.

CVS Health Corporation (CVS) has jumped on the biosimilar bandwagon by launching a wholly-owned subsidiary named Cordavis, which will work directly with manufacturers to commercialize and/or co-produce biosimilar products. A biosimilar is a biologic medication highly similar to a biologic medication already approved by the U.S. Food and Drug Administration (FDA) – the original biologic (also called the reference product).

Biosimilars are considered safe and effective as they are made from the same types of resources and do not have any meaningful differences from the reference product. Cordavis will not undertake any research and development of drugs. Cordavis has contracted with Novartis AG’s (NVS) Sandoz to commercialize and co-manufacture Hyrimoz, a biosimilar for Humira, during the first quarter of fiscal 2024, under a Cordavis private level.

The list price of this biosimilar to be brought by Cordavis will be more than 80% lower than the current list price of Humira. CVS’ CFO Shawn Guertin said, “Cordavis is a logical evolution for us and will help ensure sufficient supply of biosimilars in the U.S. and support this market now and in the future, while ultimately improving health outcomes and reducing costs for consumers.”

CVS’ Chief Pharmacy Officer and Co-President of the Pharmacy and Consumer Wellness segment, Prem Shah, said, “We have a strategy to go after the products where we believe we can create the most value for customers, and for the US marketplace where we can increase the competition, lower the cost, and get that cost to consumers, and get these products to consumers at lower prices.”

JPMorgan analyst Lisa Gill said the contract with Sandoz is a volume-based transaction with only upside for CVS. In a note, she stated, “CVS has committed to purchasing a certain amount of volume from Sandoz, and management noted there are no additional capital commitments. CVS anticipates Cordavis will generate positive margins for commercializing the product, but it is too early to size the potential contribution.”

With sales of Humira totaling more than $21 billion last year, CVS now can grab a slice of this enormous market for the expensive and vital drug.

Here’s what could influence CVS’ performance in the upcoming months:

Mixed Financials

CVS’ total revenues for the second quarter ended June 30, 2023, increased 10.3% year-over-year to $88.92 billion. For the six months ended June 30, 2023, its net cash provided by operating activities increased 48.2% over the prior-year quarter to $13.35 billion.

Its adjusted operating income declined 10.4% year-over-year to $4.48 billion. The company’s adjusted income attributable to CVS Health declined 14.7% year-over-year to $2.85 billion. Also, its adjusted EPS came in at $2.21, representing a decline of 12.6% year-over-year.

Mixed Analyst Estimates

Analysts expect CVS’ EPS for fiscal 2023 to decline 1.2% year-over-year to $8.59. Its fiscal 2023 revenue is expected to increase 8.9% year-over-year to $351.01 billion. Its EPS for fiscal 2024 is expected to increase 1.2% year-over-year to $8.69. On the other hand, its fiscal 2024 revenue is expected to decline 2% year-over-year to $344.07 billion.

Discounted Valuation

In terms of forward EV/Sales, CVS’ 0.43x is 87.8% lower than the 3.51x industry average. Its 7.54x forward EV/EBITDA is 42.3% lower than the 13.08x industry average. Likewise, its 8.57x forward EV/EBIT is 49.2% lower than the 16.86x industry average.

Mixed Profitability

In terms of the trailing-12-month levered FCF margin, CVS’ 5.33% is significantly higher than the 0.22% industry average. Likewise, its 1.41x trailing-12-month asset turnover ratio is 273.4% higher than the industry average of 0.38x. Furthermore, its 5.42% trailing-12-month EBITDA margin is 5.2% higher than the industry average of 5.15%.

On the other hand, CVS’ 0.84% trailing-12-month Capex/Sales is 81.4% lower than the 4.52% industry average. Likewise, its 15.64% trailing-12-month gross profit margin is 71.8% lower than the 55.53% industry average.

Bottom Line

CVS’ entry into the world of biosimilar products through its newly launched subsidiary Cordavis is expected to help the company boost its revenues and improve its profit margins. However, the company faces competition from other companies making a biosimilar of Humira.

Moreover, the company has yet to communicate what it intends to do after launching the Humira biosimilar during the first quarter of fiscal 2024. Until the company shares its plans, it could be risky to invest in the stock.

Given its mixed fundamentals and profitability, it could be wise to wait for a better entry into the stock.